REMETHAN 25 TABLET 25mg FOR ORAL USE

Product Information

Registration Status: Active

REMETHAN 25 TABLET 25mg is approved to be sold in Singapore with effective from 1991-08-01. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN05301P.

This product contains Diclofenac 25mg in the form of ENTERIC-COATED TABLET. It is approved for ORAL use.

This product is manufactured by REMEDICA LTD in CYPRUS.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Description

A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]

Indication

For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Mechanism of Action

The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation.

Pharmacokinetics

Absorption: Completely absorbed from the gastrointestinal tract.
Distribution: * 1.3 L/kg
Metabolism: Hepatic
Elimination

Clearance

* oral cl=622 mL/min [healthy] * renal cl <1 mL/min [healthy]

Toxicity

Symptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis. LD₅₀=390mg/kg (orally in mice)

Active Ingredient/Synonyms

Source of information: Drugbank (External Link). Last updated on: 3^rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.